Table 5.

Multivariate analysis of disease-specific survival and overall survival.

Characteristic	Disease-specific survival		Overall survival
	HR (95% CI)	p	HR (95% CI)	p
Sex
Female	Reference		Reference
Male	0.896 (0.749–1.072)	0.229	0.881 (0.763–1.017)	0.084
Primary site
Axial	Reference	–	Reference
Appendicular	0.626 (0.466–0.841)	0.002	0.694 (0.552–0.872)	0.002
Craniofacial	0.708 (0.553–0.908)	0.006	0.729 (0.597–0.889)	0.002
Laterality
Bilateral, single primary	Reference	–	Reference
Left: origin of primary	0.930 (0.489–1.771)	0.826	0.898 (0.532–1.519)	0.689
Right: origin of primary	0.853 (0.446–1.631)	0.631	0.953 (0.563–1.613)	0.859
Not a paired site	0.920 (0.486–1.744)	0.798	0.935 (0.555–1.577)	0.802
Histologic type: broad groupings
Malignant lymphomas, NOS or diffuse	Reference	–	Reference	–
Hodgkin lymphomas	0.184 (0.058–0.583)	0.004	0.392 (0.200–0.771)	0.007
NHL–mature B-cell lymphomas	0.828 (0.676–1.014)	0.067	0.826 (0.700–0.973)	0.023
NHL–mature T- and NK-cell lymphomas	0.518 (0.269–0.999)	0.050	0.680 (0.424–1.090)	0.109
NHL-precursor-cell lymphoblastic lymphoma	0.536 (0.235–1.221)	0.137	0.453 (0.223–0.923)	0.029
Ann Arbor stage
Stage I–II	Reference	–	Reference	–
Stage III–IV	1.635 (1.281–2.086)	0.000	1.348 (1.107–1.641)	0.03
Number of bone lesions
Single	Reference	–	Reference	–
Multiple (⩾2)	1.122 (0.878–1.435)	0.357	1.201 (0.990–1.457)	0.064
Surgery
No	Reference	–	Reference	–
Yes	1.162 (1.064–1.379)	0.101	1.129 (0.977–1.304)	0.101
Radiation
No	Reference	–	Reference	–
Yes	0.996 (0.559–0.710)	0.981	0.934 (0.730–1.195)	0.587
Chemotherapy
No	Reference	–	Reference	–
Yes	0.641 (0.546–0.702)	0.000	0.734 (0.605–0.890)	0.002

CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma; NK, natural killer (cell); NOS, not otherwise specified.